Growth Metrics

Gyre Therapeutics (GYRE) Net Cash Flow Growth (1y) (2011 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (1y) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 198.34%
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 467.41%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -14,223.53%
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 453.08%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -125.22%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 53.46%
10 Gyre Therapeutics 532.38 Mn 518.25 Mn 8.38 Mn -94.78%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -94.78%
Dec 31, 2025 9.58%
Sep 30, 2025 1,203.26%
Jun 30, 2025 257.52%
Mar 31, 2025 186.51%
Dec 31, 2024 -119.05%
Sep 30, 2024 -147.87%
Jun 30, 2024 -93.93%
Mar 31, 2024 26.34%
Dec 31, 2023 174.15%
Sep 30, 2023 101.35%
Jun 30, 2023 -117.30%
Mar 31, 2023 47.61%
Dec 31, 2022 -81.57%
Sep 30, 2022 -261.62%
Jun 30, 2022 530.62%
Mar 31, 2022 -118.09%
Dec 31, 2021 -372.39%
Sep 30, 2021 57.89%
Jun 30, 2021 15.04%
Mar 31, 2021 -4.20%
Dec 31, 2020 171.08%
Sep 30, 2020 -711.21%
Jun 30, 2020 -44.49%
Mar 31, 2020 988.59%
Dec 31, 2019 -59.85%
Sep 30, 2019 152.72%
Jun 30, 2019 90.41%
Mar 31, 2019 -105.79%
Dec 31, 2018 -254.16%
Sep 30, 2018 50.84%
Jun 30, 2018 -827.96%
Mar 31, 2018 4,439.29%
Dec 31, 2017 227.77%
Sep 30, 2017 -975.64%
Jun 30, 2017 216.91%
Mar 31, 2017 71.07%
Dec 31, 2016 -84.22%
Sep 30, 2016 -109.70%
Jun 30, 2016 -4,067.09%
Mar 31, 2016 -1,722.10%
Dec 31, 2015 391.40%
Sep 30, 2015 75.55%
Jun 30, 2015 114.59%
Mar 31, 2015 105.56%
Dec 31, 2014 -110.33%
Sep 30, 2014 997.20%
Jun 30, 2014 76.12%
Mar 31, 2014 23.71%
Dec 31, 2013 393.51%
Sep 30, 2013 -120.13%
Jun 30, 2013 60.04%
Mar 31, 2013 33.50%
Dec 31, 2012 117.36%
Sep 30, 2012 117.44%
Jun 30, 2012 -158.09%
Mar 31, 2012 31.10%
Dec 31, 2011 -16.61%
Sep 30, 2011 -4.95%